



Alnylam to Webcast Presentation at the CIBC Annual Biotechnology & Specialty Pharmaceuticals Conference on April 5, 2005

CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 1, 2005--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will be presenting a company overview at the CIBC Annual Biotechnology & Specialty Pharmaceuticals Conference on April 5, 2005, at 2:15 pm Eastern Time at the Millennium Broadway Hotel.

A live audio webcast of this presentation will be available on the "Investors" section of the company's website, <http://www.alnylam.com>. A replay of the presentation will be posted on the Alnylam website approximately three hours after the event, and will be archived for 30 days.

About Alnylam

Alnylam is a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on RNA interference, or RNAi. Growing from its foundation as the world's first company focused on RNAi therapeutics, the company's leadership in the field of RNAi is supported by its preeminent founders and advisors and its strengths in fundamental patents, technology, and know-how that underlie the commercialization of RNAi therapeutics. Alnylam is developing a pipeline of RNAi products using Direct RNAi™ to treat ocular, central nervous system, and respiratory diseases and Systemic RNAi(TM) to treat a broad range of diseases, including oncology, metabolic, and autoimmune diseases. The company's global headquarters are in Cambridge, Massachusetts. For additional information, please visit <http://www.alnylam.com>.

Forward Looking Statements

Various statements in this release concerning our future expectations, plans, prospects and future operating results constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our approach to discover and develop novel drugs, which is unproven and may never lead to marketable products; our ability to obtain additional funding to support our business activities; our dependence on third parties for development, manufacture, marketing, sales and distribution of our products; the successful development of products, all of which are in early stages of development; obtaining regulatory approval for products; competition from others using technology similar to ours and others developing products for similar uses; obtaining, maintaining and protecting intellectual property utilized by our products; and our short operating history; as well as those risks more fully discussed in the "Certain Factors That May Affect Future Results" section of our Annual Report on Form 10-K filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We do not assume any obligation to update any forward-looking statements.

SOURCE: Alnylam Pharmaceuticals, Inc.

CONTACT:

Investor:
Lilian Stern,
Stern Investor Relations, Inc.,
1+212-362-1200, or
Media:
Kathryn Morris,
1+845-635-9828